share_log
Reuters ·  2024/12/11 21:15

Lilly's Imlunestrant, an Oral Serd, Significantly Improved Progression-Free Survival as Monotherapy and in Combination With Verzenio® (Abemaciclib) in Patients With Er+, Her2- Advanced Breast Cancer

Lilly的Imlunestrant,一种口服选择性雌激素受体降解剂,显著改善了ER+、HER2-晚期乳腺癌患者在单药治疗和与Verzenio®(阿贝马唑)联合治疗中的无进展生存期。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发